title: A case of subacute cutaneous lupus erythematosus as a result of ranibizumab (Lucentis) treatment.
abstract: Cutaneous lupus erythematosus is a previously undiagnosed side-effect of ranibizumab. Here, we present a case of an 82-year-old female Caucasian patient with wet age-related macular degeneration. Following a single intraocular injection of Lucentis (ranibizumab), she developed a subacute cutaneous lupus erythematosus which, with treatment, took nearly 12 months to resolve. This shows that cutaneous lupus erythematosus is a potential side-effect of many medications, including ranibizumab, as in our case and, in an aging population where polypharmacy is a growing reality, clinicians should be aware of how to diagnose and best manage such cases.
authors.affiliation: Department of Ophthalmology, Royal Hobart Hospital, Tasmania, Australia.
authors.forename: Marko
authors.initials: M
authors.lastname: Andric
authors.forename: Shreya
authors.initials: S
authors.lastname: Dixit
authors.forename: Dana
authors.initials: D
authors.lastname: Robaei
authors.forename: Rosemary
authors.initials: R
authors.lastname: Watchorn
authors.forename: Nitin
authors.initials: N
authors.lastname: Verma
mesh_terms: D000369:Aged, 80 and over; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage / Q000009:adverse effects*; D001706:Biopsy; D003937:Diagnosis, Differential; D005260:Female; D005500:Follow-Up Studies; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D058449:Intravitreal Injections; D008178:Lupus Erythematosus, Cutaneous / Q000139:chemically induced* / Q000175:diagnosis / Q000188:drug therapy; D008268:Macular Degeneration / Q000188:drug therapy*; D000069579:Ranibizumab; D012867:Skin / Q000473:pathology
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D005938:Glucocorticoids; D000069579:Ranibizumab